© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 15, 2022
New studies have shown promise for updated standards of care in patients with lymphoma.
September 13, 2022
Investigators for a phase 2 study of linperlisib began dosing its first patient with relapsed/refractory peripheral T/NK cell lymphoma.
September 12, 2022
Data presented at ESMO 2022 showed GSK3326595, aPRMT5 inhibitor, to display efficacy and safety signals consistent with those that were previously reported in advanced solid tumors.
August 25, 2022
In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.
August 19, 2022
The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.
Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.
An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.
Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.
An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.
Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.